Patient selection for immunotherapy in head and neck cancer

Nancy Y Lee and colleagues1 should be congratulated for their efforts in completing this first-of-its kind phase 3 trial, providing the scientific community with relevant insights into the addition of immune checkpoint blockade to concurrent chemoradiotherapy.